Liraglutide and Semaglutide Reduce Cardiovascular Events in Patients With Type 2 Diabetes and Peripheral Arterial Disease

Citation
Verma S, Rasmussen S, Saevereid HA, Ripa MS. Circulation. 2019;140(Suppl 1):A11456.